Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...
Drug efficacy in vivo studies At InnoSer, we frequently carry out in vivo efficacy studies in a range of preclinical models (patient-derived xenografts, syngeneic models, cell-line derived xenografts) complemented with readouts such immune cell profiling and...
Introduction into the power of bioluminescence imaging Bioluminescence imaging (further referred to as BLI in this article) is an in vivo imaging technique that allows non-invasive longitudinal monitoring of in vivo processes, commonly applied in preclinical oncology...
